The 2021 NCCN Clinical Practice Guidelines for Colon Cancer have introduced updated recommendations for systemic therapy in metastatic colorectal cancer, underscoring the importance of biomarker testing in guiding treatment decisions. This revision reflects the evolving landscape of precision medicine, where targeted therapies are increasingly informed by molecular profiling. By integrating biomarker-driven approaches into clinical practice, the guidelines aim to optimize patient outcomes and enhance the efficacy of systemic therapy in metastatic colorectal cancer, thereby setting a new standard of care in the management of this malignancy.